PolyPeptide Group stock
PPGN.SWSIXPolyPeptide Group AG, HealthcareISIN CH1110760852
42Score 42 out of 100, Weak
Price and trend
54 / 100
Price history
+70% in one yearThe chart shows daily closes over 6 years, adjusted for stock splits and without dividends. Click into the chart to set a price alert at that price.
Above the 200-day line: the price is 6.2% above it.
Since August 2025 the 50-day line has been above the 200-day line; the trend has turned up.
Sharply down: the price has fallen very quickly lately (RSI 24).
The price is 18% below its 52-week high. Largest decline in 6 years: 90% (September 2021 to April 2025).
Chart figures for advanced users
- SMA 50$52.08
- Average price of the last 50 trading days, shows the short-term trend.
- SMA 200$45.65
- Average price of the last 200 trading days, shows the long-term trend.
- RSI (14)24
- Relative strength over the last 14 days on a scale from 0 to 100. Above 70 the price counts as overheated, below 30 as sharply fallen.
- MACDbelow the signal line
- Compares a fast and a slow price average. Above its signal line momentum is rising, below it momentum is fading.
- Support$26.35
- The lowest closing price of the last twelve months.
- Resistance$59.29
- The highest closing price of the last twelve months.
Snapshot
Computed from the data by fixed rules, no AI
- PolyPeptide Group AG belongs to the Drug Manufacturers (Specialty & Generic) industry (Switzerland) and, with a market value of $1.6B, is number 58 of 77 companies in its industry on MEQIRI.
- In fiscal 2025 it reported revenue of $434.23M (up 15.7% year on year) and a loss of $23.61M.
- MEQIRI Score 42 out of 100 (Weak): rank 510 of 702 in Healthcare, median 53.
Show more
- The P/E is 100 (Drug Manufacturers (Specialty & Generic) median 18.9, own median of recent years 98.2).
- Our model puts fair value at $33.96, with the price 43% above it.
In plain words
The numbers on this page in plain words, written by an AI
Strengths
- Analysts expect strong earnings growthUp 48.4% a year through 2028 (estimates from 4 analysts).
Weaknesses
- Interest barely coveredOperating profit covers interest only 0.4 times.Stability 54
- Turned to a lossEarnings per share from $1.15 in 2020 to −$0.71.Growth 36
- Negative free cash flowFree cash flow −$55.12M over the last 12 months.Fundamentals 35
Its standout strength is momentum, while capital allocation and valuation hold the score back.
Daily figure as of 13 Nov 2026
How the score is calculatedScore overview
Fundamental quality fluctuates.
Score history
The full history of up to 20 years comes with MEQIRI Pro.
See plansCrash risk high
How well MEQIRI warnsOne of the 30% with the highest crash risk among smaller stocks.
From 2016 to 2025, 36 in 100 such stocks fell 30% or more within a year, against a group average of 23 in 100.
What drives the risk
- weak fundamentals
Valuation
Valuation signal
Modestly overvaluedIn our model the price counts as cheap below $24.26 and expensive above $56.61 (uncertainty high, based on the price swings of the past year).
The two parts of the fair value come to $58.75 (cash-flow model) and $9.17 (industry comparison), and the gap between them shows how uncertain the estimate is.
Calculated with a cost of equity of 7.1%. At 8.1% the fair value would be $28.90, at 6.1% it would be $41.57.
Valuation metrics
Half from the cash-flow model, half from earnings times the industry P/E (18.9).
Calculate with your own assumptionsCompany performance
This shows several years of history with an automatic assessment.
Revenue
In the twelve months to 30 Jun 2026, revenue rose 24.4% on the twelve months before. Revenue has grown solidly since 2018, at about 12% per year.
Margins
- Gross margin
- Operating margin
- Net margin
In fiscal 2025: gross 16%, operating 2%, net −5%. Last 12 months: net 3%.
Debt & balance sheet
latest quarterDebt is moderate, but interest coverage is weak. Keep an eye on the interest burden and refinancing.
Earnings
- Next earnings
- 9 Mar 2027in 116 days
- Last reported
- 13 Aug 2026EPS reported 0.25 (expected 0.06)above expectations
Analyst estimates
Earnings estimates have barely changed since 15 Oct 2026.
- Earnings per share
- 0.85+1.7%
- Revenue
- $554.96M−1.1%
- Earnings per share
- 1.51+1.0%
- Revenue
- $625.88M−1.5%
MEQIRI has stored the estimates since 15 Oct 2026. Until 30 days are available, the card shows the change since that day. Mean estimate according to Financial Modeling Prep. No price target and no recommendation.
What happened at PolyPeptide Group
The key events of the last six months from our own data. A click takes you to the matching card.
Sector comparison
702 rated companies in Healthcare
- This company
- 42
- Sector median
- 53
Categories against the sector median
The median is the middle value: half of the companies in the sector lie above it, half below. Categories with too few comparable companies are left out.
Competitors in Drug Manufacturers (Specialty & Generic)
The next larger and next smaller companies by market value
- Faes FarmaFAE.MC $1.72B70
- SupernusSUPN $1.7B62
- AlvotechALVO $1.67B42
- ANI PharmaceuticalsANIP $1.63B61
- Pacira BioSciencesPCRX $1.46B58
- Phibro Animal HealthPAHC $1.44B57
- Cronos GroupCRON $1.25B61
- BioGaiaBIOG-B.ST $1.24B77
ETFs that hold PolyPeptide Group
Held by 4 ETFs on Xetra. Shown per index: the ETF with the largest weight.
| ETF | Weight | Cost | Fund size |
|---|---|---|---|
| Amundi MSCI Europe Small Cap ESG Broad Transition UCITS ETF DistX026 | 0.06% | 0.23% | €321.86M |
| Xtrackers MSCI Europe Small Cap UCITS ETF 1CXXSC | 0.04% | 0.30% | €3.45B |
| Vanguard ESG Global All Cap UCITS ETF (USD) AccumulatingV3AA | 0.00% | 0.24% | €1.69B |
Show 1 more
| Vanguard FTSE Global All-Cap UCITS ETF Accum USDVGLA | 0.00% | 0.07% | €3.9B |
Holdings as reported by the funds via FMP, excluding swap ETFs (their holdings are only collateral).
Data status and sources
- Score
- Daily value of 13 Nov 2026, recalculated nightly
- Price
- Closing price of 12 Nov 2026
- Latest annual report
- Fiscal year 2025, period end 31 Dec 2025
- Currency
- Amounts in US dollars, converted at the ECB reference rate of 12 Nov 2026 ($1 = CHF 0.8331, $1 = €0.9024)
- Source
- Financial statements, ratios and prices from Financial Modeling Prep (FMP), based on the company's reports. MEQIRI calculates the score and fair value from them.
Mandatory disclosures for this rating
- ; time horizon around 12 months
- Rated Weak, published since 7 Nov 2026 (in the score history since 30 Apr 2023)
- Valuation signal Fairly valued since 7 Nov 2026
- End-of-day prices, metrics cached for up to 24 hours
- Score and fair value are estimates from a disclosed model. They are not facts and not a price target.
- Produced by SSM Ventures UG (haftungsbeschränkt), responsible person Sven Brostmeyer, Managing Director, automatically according to the disclosed model.
- Not investment advice. Losses up to and including a total loss are possible. Personal circumstances are not considered.